Absci Corporation - Common Stock (ABSI)
3.1200
+0.0200 (0.65%)
Absci Corp is a biotechnology company that focuses on advancing the development of protein-based therapeutics through its innovative AI-driven platform
The company combines synthetic biology with machine learning to enhance the discovery, design, and production of complex proteins and antibodies. Absci’s technology aims to revolutionize the way biologic drugs are developed, enabling faster and more efficient creation of new drug candidates to address unmet medical needs in various therapeutic areas. By leveraging its proprietary platform, Absci aims to support pharmaceutical and biotech partners in bringing next-generation therapies to market.

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via Benzinga · March 8, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · February 17, 2025

Via Benzinga · January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
Via Benzinga · January 22, 2025

Via Benzinga · January 17, 2025

Via Benzinga · January 22, 2025

Via Benzinga · January 22, 2025

Via Benzinga · January 22, 2025

Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.
Via Benzinga · January 22, 2025

Via Benzinga · January 8, 2025

Via Benzinga · January 8, 2025

Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators and ROCm software.
Via Benzinga · January 8, 2025

Via Benzinga · December 12, 2024

Via Benzinga · December 10, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
Via Talk Markets · September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
Via Talk Markets · September 10, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day.
Via Talk Markets · September 5, 2024

The popular growth investor keeps adding to some of her favorite falling stocks.
Via The Motley Fool · August 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.
Via Talk Markets · August 27, 2024

ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion by then.
Via Talk Markets · August 14, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via Talk Markets · July 30, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
Via Talk Markets · July 14, 2024